Generic drugmaker Zydus Lifesciences Ltd has announced the launch
of olaparib, a PARP inhibitor, under the brand name IBYRA in India. This move
aims to provide advanced cancer treatment at a significantly lower price,
making it accessible to a wider population.
IBYRA targets specific genetic mutations found in certain types of
cancers, allowing for a more tailored and effective treatment approach. It is
particularly beneficial for patients diagnosed with HRD (homologous
recombination deficiency) positive or BRACA mutation-associated cancers, where
IBYRA can help delay disease progression.
Collaborating with MedGenome, Zydus offers comprehensive HRD
testing to identify eligible patients and facilitate access to IBYRA treatment.
The cost of both testing and a year-long course of IBYRA has been capped at ?3
lakh, making it substantially more affordable compared to the innovator's price
of around ?72 lakh.
Dr. Sharvil Patel, Managing Director of Zydus Lifesciences,
emphasizes the importance of early diagnosis and precise treatment for cancer
patients. He highlights Zydus' patient-centric approach in launching IBYRA,
aiming to provide cutting-edge diagnosis and precision therapy at an affordable
cost.
Shares of Zydus Lifesciences Ltd closed at ?968.65 on the BSE,
reflecting the market's response to this significant development.
